KR20170132879A - 조합 요법을 위한 약제학적 조성물 - Google Patents

조합 요법을 위한 약제학적 조성물 Download PDF

Info

Publication number
KR20170132879A
KR20170132879A KR1020177031857A KR20177031857A KR20170132879A KR 20170132879 A KR20170132879 A KR 20170132879A KR 1020177031857 A KR1020177031857 A KR 1020177031857A KR 20177031857 A KR20177031857 A KR 20177031857A KR 20170132879 A KR20170132879 A KR 20170132879A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
therapeutic agent
additional therapeutic
insulin
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177031857A
Other languages
English (en)
Korean (ko)
Inventor
마르크 프루잔스키
루치아노 아도리니
Original Assignee
인터셉트 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인터셉트 파마슈티컬즈, 인크. filed Critical 인터셉트 파마슈티컬즈, 인크.
Publication of KR20170132879A publication Critical patent/KR20170132879A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177031857A 2015-04-07 2016-04-06 조합 요법을 위한 약제학적 조성물 Ceased KR20170132879A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144040P 2015-04-07 2015-04-07
US62/144,040 2015-04-07
PCT/US2016/026146 WO2016164413A1 (en) 2015-04-07 2016-04-06 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
KR20170132879A true KR20170132879A (ko) 2017-12-04

Family

ID=57072872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177031857A Ceased KR20170132879A (ko) 2015-04-07 2016-04-06 조합 요법을 위한 약제학적 조성물

Country Status (25)

Country Link
US (1) US10894054B2 (OSRAM)
EP (1) EP3280421B1 (OSRAM)
JP (1) JP6879931B2 (OSRAM)
KR (1) KR20170132879A (OSRAM)
CN (1) CN107613986A (OSRAM)
AR (1) AR104195A1 (OSRAM)
AU (1) AU2016246524B2 (OSRAM)
BR (1) BR112017021311A2 (OSRAM)
CA (1) CA2981507A1 (OSRAM)
CL (2) CL2017002538A1 (OSRAM)
CO (1) CO2017010292A2 (OSRAM)
CR (1) CR20170456A (OSRAM)
EA (1) EA036757B1 (OSRAM)
EC (1) ECSP17073004A (OSRAM)
ES (1) ES2974281T3 (OSRAM)
IL (2) IL254772A0 (OSRAM)
MA (1) MA41083A1 (OSRAM)
MX (1) MX2017012893A (OSRAM)
NI (1) NI201700121A (OSRAM)
PE (1) PE20180034A1 (OSRAM)
SM (1) SMT202400104T1 (OSRAM)
SV (1) SV2017005539A (OSRAM)
TN (1) TN2017000426A1 (OSRAM)
TW (1) TW201642869A (OSRAM)
WO (1) WO2016164413A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021029656A1 (ko) * 2019-08-14 2021-02-18 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11267861B2 (en) 2016-04-19 2022-03-08 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
CN116790476A (zh) 2016-05-05 2023-09-22 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
KR102546194B1 (ko) * 2016-11-04 2023-06-21 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
KR102558606B1 (ko) 2016-12-05 2023-07-26 칠드런즈 호스피탈 메디칼 센터 결장 유사장기 및 이를 제조 및 사용하는 방법
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
EP3694603A4 (en) 2017-10-10 2021-07-14 Children's Hospital Medical Center ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
JP2021522247A (ja) * 2018-04-24 2021-08-30 ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 肝疾患における好中球エラスターゼ阻害薬の使用
JP7506657B2 (ja) 2018-07-26 2024-06-26 チルドレンズ ホスピタル メディカル センター 肝胆膵組織およびその作製方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US12428622B2 (en) 2018-09-12 2025-09-30 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
WO2020081766A1 (en) * 2018-10-18 2020-04-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
WO2020108830A1 (en) * 2018-11-30 2020-06-04 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
AU2020247991A1 (en) * 2019-03-26 2021-10-21 Intercept Pharmaceuticals, Inc. Methods of diagnosis and treatment of liver diseases using obeticholic acid
US20220288054A1 (en) * 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
JP7610533B2 (ja) 2019-05-31 2025-01-08 チルドレンズ ホスピタル メディカル センター 造血幹細胞の生成および拡大方法
EP4277630A1 (en) * 2021-01-14 2023-11-22 ENYO Pharma Method for treating chronic kidney diseases
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
CA3250533A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR TREATING EXCESS GLUCOCORTICOIDS
WO2023240204A2 (en) * 2022-06-08 2023-12-14 Kojin Therapeutics, Inc. Methods and compositions for initiating, regulating, and modulating weight loss and therapeutic applications thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
AU2389100A (en) 1998-12-23 2000-07-12 Glaxo Group Limited Assays for ligands for nuclear receptors
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
CN1151140C (zh) * 1999-03-29 2004-05-26 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
DE60205891T2 (de) 2001-03-12 2006-06-22 Intercept Pharmaceuticals, Inc. Steroide als agonisten für fxr
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2003086303A2 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
TW200521131A (en) * 2003-08-01 2005-07-01 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
AU2004261264A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-O-glucosides
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
EP3175855B1 (en) 2004-03-12 2020-07-15 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
WO2007024700A2 (en) * 2005-08-19 2007-03-01 Amylin Pharmaceuticals, Inc. Exendin for treating diabetes and reducing body weight
WO2007022518A2 (en) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
JP5081161B2 (ja) * 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
BRPI0707794A2 (pt) 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos
CN101448791B (zh) 2006-05-24 2011-11-16 伊莱利利公司 Fxr激动剂
AR061101A1 (es) 2006-05-24 2008-08-06 Lilly Co Eli Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende
PL2040713T3 (pl) 2006-06-27 2014-11-28 Intercept Pharmaceuticals Inc Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
US20100056546A1 (en) * 2008-09-04 2010-03-04 Auspex Pharmaceuticals, Inc. Sulfonylurea inhibitors of atp-sensitive potassium channels
CN102639125A (zh) * 2009-05-27 2012-08-15 百时美施贵宝公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9655920B2 (en) * 2010-02-24 2017-05-23 Relypsa, Inc. Amine polymers for use as bile acid sequestrants
US9775556B2 (en) 2010-05-26 2017-10-03 Andre′ A. DiMino Apparatus and method for uroflowmetry
EP4137137A1 (en) * 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
JP5983407B2 (ja) 2010-09-15 2016-08-31 住友電気工業株式会社 レーザ加工方法
WO2012106581A1 (en) * 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
PT3336097T (pt) 2012-06-19 2020-10-29 Intercept Pharmaceuticals Inc Preparação da forma não cristalina de ácido obeticólico
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
EA030152B1 (ru) 2013-05-14 2018-06-29 Интерсепт Фармасьютикалз, Инк 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021029656A1 (ko) * 2019-08-14 2021-02-18 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물

Also Published As

Publication number Publication date
US10894054B2 (en) 2021-01-19
JP6879931B2 (ja) 2021-06-02
CA2981507A1 (en) 2016-10-13
CR20170456A (es) 2018-06-13
WO2016164413A1 (en) 2016-10-13
US20180117065A1 (en) 2018-05-03
NI201700121A (es) 2018-01-10
CN107613986A (zh) 2018-01-19
ES2974281T3 (es) 2024-06-26
CL2018001007A1 (es) 2018-06-15
IL268316B (en) 2022-02-01
MX2017012893A (es) 2018-01-15
TN2017000426A1 (en) 2019-04-12
IL254772A0 (en) 2017-12-31
ECSP17073004A (es) 2018-02-28
EP3280421A4 (en) 2019-08-28
EP3280421B1 (en) 2023-12-27
CL2017002538A1 (es) 2018-04-20
IL268316A (en) 2019-09-26
CO2017010292A2 (es) 2018-01-05
TW201642869A (zh) 2016-12-16
EP3280421A1 (en) 2018-02-14
PE20180034A1 (es) 2018-01-09
JP2018510900A (ja) 2018-04-19
EA201792203A1 (ru) 2018-02-28
BR112017021311A2 (pt) 2018-06-26
AU2016246524A1 (en) 2017-10-26
AU2016246524B2 (en) 2021-04-01
AR104195A1 (es) 2017-07-05
SV2017005539A (es) 2019-01-18
MA41083A1 (fr) 2018-05-31
SMT202400104T1 (it) 2024-05-14
EA036757B1 (ru) 2020-12-17

Similar Documents

Publication Publication Date Title
KR20170132879A (ko) 조합 요법을 위한 약제학적 조성물
Mukherjee et al. Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration
JP7306791B2 (ja) 併用療法のための医薬組成物
JP2021155436A (ja) シクロデキストリンを使用するための方法
KR102378462B1 (ko) 비알코올성 간질환 동물 모델 및 비알코올성 간질환의 진단, 예방 또는 치료용 조성물
US20220143003A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
KR20170049606A (ko) 간 질환을 치료하기 위한 오메가-3 지방산과 sglt-2 억제제의 조합
KR20190117632A (ko) Ppar 효현제와 fxr 효현제의 병용
EP3878470A1 (en) Method for removing senescent cell, and method for preparing senescent cell
US20240066020A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
Sujishi et al. Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice
Yada et al. The Kampo medicine “Daikenchuto (TU-100)” prevents bacterial translocation and hepatic fibrosis in a rat model of biliary atresia
EP3946336A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
Yang et al. Intestinal GSTpi deficiency exacerbates the severity of experimental hyperlipidemic acute pancreatitis
EP3517108A1 (en) Application of src homology region 2-containing protein tyrosine phosphatase-1 agonist for improving fibrosis
US20230405078A1 (en) Detection and treatment of intestinal fibrosis
Chen et al. Therapeutic effects of D-cycloserine in mouse models of IBD and CAC: Targeting NLRP3 inflammasome and intestinal barrier integrity
HK1242970A1 (en) Pharmaceutical compositions for combination therapy
WO2020173973A1 (en) Glp-1 and glucagon receptor co-agonists for use for treating nash
EP4424317A1 (en) Medicine for preventing or treating enteritis and intestinal cancer
CN121154625A (zh) 5-甲氧基邪蒿素在制备用于预防和/或治疗胆汁淤积性肝病的药物中的应用
van Mierlo et al. The FXR agonist obeticholic acid does not stimulate liver regeneration in hepatectomized mice
Xu et al. Targeting Hyaluronic Acid Synthase-3 (HAS3) for the Treatment of Advanced Renal Cell Carcinoma
Brawerman Maternal resveratrol supplementation in gestational diabetes prevents cardio-metabolic disease development and improves cardiac structure in the rat offspring
Gonzalez-Sanchez et al. BBA-Molecular Basis of Disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210406

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221215

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230405

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221215

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I